Scintigraphic images of tumor-bearing mice 24 hours post-injection with: a) CasKi tumor, E6-specific mAb ¹⁸⁸Re-C1P5 mAb; b) CasKi tumor, control ¹⁸⁸Re-18B7 mAb; c) Hep 3B2.1-7 and A2058 human metastatic melanoma tumors, HBx-specific ¹⁸⁸Re-4H9 mAb.

<p>Scintigraphic images of tumor-bearing mice 24 hours post-injection with: a) CasKi tumor, E6-specific mAb ¹⁸⁸Re-C1P5 mAb; b) CasKi tumor, control ¹⁸⁸Re-18B7 mAb; c) Hep 3B2.1-7 and A2058 human metastatic melanoma tumors, HBx-specific ¹⁸⁸Re-4H9 mAb.</p

Expression of E6 and E7 in human cervical carcinoma cell lines and of HBx in hepatocellular carcinoma cell line by Western blot and effect of MG132 proteasome inhibitor treatment on the levels of E6, E7 and HBx in these cell lines:

<p>a) E6 from protein extracts of CasKi cells treated with MG132 for 3 hrs; b) E7 from protein extracts of CasKi cells treated with MG132 for 3 hrs; c) E6 from protein extracts of CasKi cells treated with MG132 for 6 hrs; d) E7 from protein extracts of SiHa cells treated with MG132 for 3 hrs; e) E7 from protein extracts of HeLa S3 cells treated with MG132 for 3 hrs; f) HBX from protein extracts of Hep 3B2.1-7 cells treated with MG132 for 3 hrs.</p

Radioimmunotherapy of CasKi tumors in nude mice:

<p>a) changes in tumor volume; b) mouse treated with 350 µCi ¹⁸⁸Re-C1P5 mAb; c) control mouse (both mice shown on Day 20 post-treatment).</p

Radioimmunotherapy of Hep 3B2.1-7 tumors in nude mice:

<p>a) changes in tumor volume; b) control untreated mouse; c) mouse treated with 600 µCi ¹⁸⁸Re-4H9 mAb. Both mice shown on Day 18 post-treatment. In b and c lower panels show H&E stained tumors at the completion of the experiment.</p

Detection of viral antigens in tumor cells and in tumors:

<p>a, b) immunofluorescence of fixed and permeabilized tumor cells. Left panels show light microscopy images of the cells. Heavily damaged cells are marked with arrows. Right panels show immunofluorescent images of the same slides treated with viral protein-specific mAbs followed by FTIC-conjugated polyclonal antibody to mouse IgGs: a–CasKi cells and E6-specific C1P5 mAb, b-Hep 3B2.1-7 cells and HBx-specific 4H9 mAb; c) immunohistochemistry of CasKi tumors. Left panel shows binding of E6-specific mAb C1P5. Right panel shows absence of binding of control mAb 18B7; d) western blot of Hep 3B2.1-7 tumor with HBx-specific mAb 4H9.</p